Adstiladrin (nadofaragene firadenovec) intravesical therapy — Coverage Criteria
Customize your policy alerts
Sign up for all Aspirus Arise policy alerts
Know when Aspirus Arise releases new policies or updates existing guidance.
Monitor payer policy activity
Prior-authorization and coverage criteria for Adstiladrin for adults with high-risk BCG-unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS with or without papillary tumors, for Aspirus Arise plans.
Approval duration language changed to 'approve for the duration noted' and initial therapy approval set to 4 months to allow 2 doses (3 months apart).
Added requirement that Adstiladrin be prescribed by or in consultation with a urologist or oncologist.
Reworded indication option to 'Patient has Ta/T1 papillary tumors without CIS.'
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.